News, Events & Press Releases

Food and Drug Administration (FDA) Approval of GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences’ EPIDIOLEX® (cannabidiol) CV Marks First Drug Approval and Scheduling Decision Supported by Analgesic Solutions’ MADDERS® System

Drug Enforcement Agency (DEA) Places FDA-Approved Drug Containing CBD in Schedule V WAYLAND, Mass., Oct. 22, 2018 /PRNewswire/ -- Analgesic Solutions LLC is proud to announce Greenwich Bioscience's EPIDIOLEX marks the first medication approval and scheduling decision supported by data from the Misuse, Abuse and Diversion Drug Event Reporting System (MADDERS®). EPIDIOLEX was approved by the FDA June 25, 20181. FDA approval and DEA rescheduling of EPIDIOLEX from Schedule I to Schedule V (which the DEA defines as ...
Read Full Story

Analgesic Solutions Leadership Structure Update

WAYLAND, Mass., Sept. 21, 2018 /PRNewswire/ -- Analgesic Solutions LLC, a company that focuses on increasing assay sensitivity in the conduct of clinical trials through consulting, innovative tools, data science, technology and training, announced today changes within its leadership structure. Effective immediately, Robert Newman is promoted to Chief Executive Officer from Chief Operating Officer, Nathaniel P. Katz, MD, MS will move from Chief Executive Officer to Founder & Chief Scientific Officer, Andrea Licari is promoted to Chief Operating Officer from Vice President, Operations, and Arturo ...
Read Full Story

Analgesic Solutions Pain Research Methodology Applicable Across Therapeutic Spectrum

Keynote Speaker at Drug Information Association Meeting Emphasizes the Need for Better Pain Research WAYLAND, Mass., June 25, 2018 /PRNewswire/ -- Nora Volkow, MD, Director, National Institute on Drug Abuse (NIDA), National Institutes for Health (NIH), opened the 2018 Drug Information Association (DIA) Meeting in Boston with the Keynote Address emphasizing the need for new approaches for treating pain. As an industry leader in the design and execution of pain clinical trials, Analgesic Solutions, LLC’s ...
Read Full Story

Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS®)

Company Establishes Scientific Advisory Board for the MADDERS WAYLAND, Mass., June 11, 2018 /PRNewswire/ -- Analgesic Solutions, LLC announced today that Dr. Ryan Lanier will be presenting results from the implementation of the company’s proprietary Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS) at the ongoing College on Problems of Drug Dependence 80th Annual Scientific Meeting in San Diego. MADDERS was utilized to assess potentially abuse-related events in Nektar Therapeutic’s SUMMIT-07 Phase 3 clinical ...
Read Full Story

Analgesic Solutions to Present Posters at Five Conferences in 2018

Analgesic Solutions will present proprietary tools and research posters at five conferences in 2018. We invite you to meet our team presenting the following research posters. If you would like to schedule a meeting at any of the conferences or would like to learn more about the information being presenting, please contact Tony May at or 781-444-9605 x120. Poster Presentations April 2018 American Academy of Pain (Vancouver, Canada): “Assessment of a Systematic Framework to Determine ...
Read Full Story
Scroll to top